ANDA 207773, held by Zydus Lifesciences. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 207773 (Doxycycline Hyclate), held by Zydus Lifesciences, was first approved by FDA on Oct 30, 2017, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 27, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 27, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 30, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters